Saturday, June 20, 2020 11:23:47 AM
My long answer. Investing is always complicated.
1) All of my research indicates in a fair nation, CYDY will receive FDA Approval. First for Covid because one political party is using it as a weapon. The only way to open the US again is to do it and not be afraid of death. Leron removes the death.
2) HIV FDA Approval, now likely in January of 2021.
Both huge markets.
Then the FDA Trials for Cancer go at full steam with plenty of cash.
Now my worst outcome fear and if you check my past posts I have been writing this since 80 Cents.
The Hostile Buy Out.
If I was the CEO of a Gilead type Big Pharma I would be ready to attack. In fact I would have my paid lobby be in touch with the FDA. If Approval can no longer be stalled, (the election is coming) and I was the CEO of any Big Pharma I would attack now.
So is a buy out possible ? I say this with dread, Yes.
Can we , CYDY defend? Yes. If we have earnings when they attack we can simply tender for CYDY share. A self Tender. UK in 1996. Check out what UK, Union Carbide did. All it takes is imagination and cash. The self tender removes our weak shareholders.
If Big Pharma attacks and 50.1% of shareholders are weak or politely speaking; they have a different Big Picture we are toast. If 50.1% are strong Big Picture shareholders we survive.
Yes sure. We all make a large profit with a Buy Out. I just think we will be letting another company benefit. We can buy shares or possibly receive the Big Pharma shares in exchange for CYDY shares. But that dilutes Leron.
I hope this gives a clear understanding about possible buy outs, the pluses and the huge negative; dilution of Leron.
1) All of my research indicates in a fair nation, CYDY will receive FDA Approval. First for Covid because one political party is using it as a weapon. The only way to open the US again is to do it and not be afraid of death. Leron removes the death.
2) HIV FDA Approval, now likely in January of 2021.
Both huge markets.
Then the FDA Trials for Cancer go at full steam with plenty of cash.
Now my worst outcome fear and if you check my past posts I have been writing this since 80 Cents.
The Hostile Buy Out.
If I was the CEO of a Gilead type Big Pharma I would be ready to attack. In fact I would have my paid lobby be in touch with the FDA. If Approval can no longer be stalled, (the election is coming) and I was the CEO of any Big Pharma I would attack now.
So is a buy out possible ? I say this with dread, Yes.
Can we , CYDY defend? Yes. If we have earnings when they attack we can simply tender for CYDY share. A self Tender. UK in 1996. Check out what UK, Union Carbide did. All it takes is imagination and cash. The self tender removes our weak shareholders.
If Big Pharma attacks and 50.1% of shareholders are weak or politely speaking; they have a different Big Picture we are toast. If 50.1% are strong Big Picture shareholders we survive.
Yes sure. We all make a large profit with a Buy Out. I just think we will be letting another company benefit. We can buy shares or possibly receive the Big Pharma shares in exchange for CYDY shares. But that dilutes Leron.
I hope this gives a clear understanding about possible buy outs, the pluses and the huge negative; dilution of Leron.
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
